GGrantIndex
Sort

51,593 grants matching hepatitis

Longitudinal integration of environmental exposures, omics, and childhood NAFLD (LEON) Study

$784,467
Vaia Lida Chatzi · University Of Southern California · U01 · FY2025 · HG

Beyond BMI: Role of Body Composition, Coronary Microvascular Dysfunction and HFpEF in Characterizing Cardiometabolic Disease Phenotypes

$784,362
Viviany R Taqueti · Brigham And Women'S Hospital · R01 · FY2025 · HL

Nutrition, terminal NAD metabolites and cardiovascular disease

$784,329
Stanley L Hazen · Cleveland Clinic Lerner Com-Cwru · R01 · FY2025 · HL

Nutrition, terminal NAD metabolites and cardiovascular disease

$784,329
Stanley L Hazen · Cleveland Clinic Lerner Com-Cwru · R01 · FY2024 · HL

Spectinomycin analogs for NTM infections

$784,246
Richard Edward Lee · St. Jude Children'S Research Hospital · R01 · FY2023 · AI

Infection-homing nanosystems as antibacterial therapeutics-delivery platforms

$784,101
Michael J Sailor · University Of California, San Diego · R01 · FY2021 · AI

Chemical Stabilization of shRNAs and their development as hepatitis C drugs

$783,579
Brian H. Johnston · Somagenics, Inc. · R44 · FY2013 · AI

Modeling immune impairments and pathogenesis in novel humanized mice for HBV-HIV co-infection

$783,487
Lishan Su · Univ Of North Carolina Chapel Hill · R01 · FY2019 · AI

Extracellular vesicle cargo and risk of NAFLD and NASH in Latino youth

$783,329
Johanna K Distefano · Translational Genomics Research Inst · R01 · FY2023 · DK

Modeling immune impairments and pathogenesis in novel humanized mice for HBV-HIV co-infection

$783,177
Lishan Su · University Of Maryland Baltimore · R01 · FY2022 · AI

Modeling immune impairments and pathogenesis in novel humanized mice for HBV-HIV co-infection

$783,177
Lishan Su · University Of Maryland Baltimore · R01 · FY2021 · AI

A Rhesus Macaque Model of HIV and HBV co-infection

$782,991
Benjamin J Burwitz · Oregon Health & Science University · R01 · FY2024 · AI

Novel IL-23 inhibitor for the treatment of alcohol associated liver disease

$782,852
Rohit Loomba · University Of California, San Diego · U01 · FY2020 · AA

HIV AND HEPATITIS IN YOUNG INJECTORS: A COMMUNITY STUDY

$782,773
University Of California San Francisco · R01 · FY2001 · DA

2/2 Sickle Cell Disease and CardiovAscular Risk - Red cell Exchange Trial (SCD-CARRE Trial)

$782,512
Maria Mori Brooks · University Of Pittsburgh At Pittsburgh · U24 · FY2022 · HL

Bupropion for smoking cessation during pregnancy

$782,511
Gary D Hankins · University Of Texas Med Br Galveston · R01 · FY2015 · DA

NIH Director's Pioneer Award

$782,500
Karla Kirkegaard · Stanford University · DP1 · FY2006 · OD

Screening for AL Amyloidosis in Smoldering Multiple Myeloma

$782,391
Raymond Luke Comenzo · Tufts Medical Center · R01 · FY2025 · CA

Core J: Virology and Molecular Biomarkers Core

$782,351
Guido Silvestri · Emory University · P30 · FY2020 · AI

The Impact of Mitochondrial Repression and Lipid Accumulation by HIF on Tumor Growth

$782,337
Amato J. Giaccia · Stanford University · R35 · FY2015 · CA

SPECS: Safe Pediatric Euglycemia in Cardiac Surgery

$782,159
Michael Agus · Boston Children'S Hospital · R01 · FY2011 · HL

Discovery of Antivirals Targeting Mpox Virus

$782,142
Stefan G Sarafianos · Emory University · R01 · FY2024 · AI

Fourier transform-ion cyclotron-resonance mass spec

$782,028
Institute For Systems Biology · S10 · FY2003 · RR

Development and validation of a novel 3D human in vitro model of nonalcoholic steatohepatitis to be used for novel therapeutic screening and research on disease mechanism.

$782,018
Alice Chen · Organovo, Inc. · R44 · FY2018 · DK

Community-based, client-centered prevention homes to address the rural opioid epidemic

$781,715
Ryan Patrick Westergaard · University Of Wisconsin-Madison · UH3 · FY2019 · DA